Omega Therapeutics, Inc. (OMGA)
Pre-market:
| Previous close | 2.2800 |
| Open | 2.3500 |
| Bid | 2.1400 x 400 |
| Ask | 2.1700 x 400 |
| Day's range | 2.1500 - 2.3600 |
| 52-week range | 1.3000 - 10.0900 |
| Volume | |
| Avg. volume | 395,675 |
| Market cap | 118.859M |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.6600 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.83 |
Simply Wall St.Omega Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
Omega Therapeutics ( NASDAQ:OMGA ) First Quarter 2024 Results Key Financial Results Net loss: US$20.1m (loss narrowed...
ZacksOmega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 5.26% and 155.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireOmega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data demonstrating potential of a MYC-targeting epigenomic controller in NSCLC at AACR 2024Company to present new preclinical data demonstrating durable epigenomic upregulation and other OMEGA platform capabilities at ASGCT 2024 CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (
